Get the Stockscreener App
1.50
1.96%
-0.03
Fortress Biotech Inc stock is traded at $1.50, with a volume of 246.11K.
It is down -1.96% in the last 24 hours and down -12.28% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
See More
Previous Close:
$1.53
Open:
$1.5
24h Volume:
246.11K
Relative Volume:
0.84
Market Cap:
$46.40M
Revenue:
$80.97M
Net Income/Loss:
$-78.31M
P/E Ratio:
-0.1353
EPS:
-11.0849
Net Cash Flow:
$-129.56M
1W Performance:
-4.46%
1M Performance:
-12.28%
6M Performance:
-15.73%
1Y Performance:
-14.29%
1-Day Range:
$1.46
$1.57
1-Week Range:
$1.45
$1.6366
52-Week Range:
$1.325
$2.89
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
1.50 | 46.40M | 80.97M | -78.31M | -129.56M | -11.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
Fortress Biotech Board Member Resigns for New Role - TipRanks
When the Price of (FBIOP) Talks, People Listen - news.stocktradersdaily.com
Fortress Biotech (NASDAQ:FBIOP) Trading Down 2.1% – What’s Next? - Defense World
This Fortress Biotech Insider Increased Their Holding By 26% Last Year - Yahoo Finance
Roth Capital Forecasts Reduced Earnings for Fortress Biotech - Defense World
FBIO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Fortress Biotech, Inc. Investors of Important Tuesday Deadline in Securities Class ActionFBIO - MarketScreener
SEC Form POS AM filed by Fortress Biotech Inc. - Quantisnow
Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Fortress Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech Transforms Portfolio: Dual FDA Wins, $28M Deal, Latest Earnings - Stock Titan
Fortress Biotech, Inc. (NASDAQ:FBIO) Q4 2024 Earnings Call Transcript - Insider Monkey
Fortress Biotech’s Mixed Earnings Call: Emrosi’s Launch and Challenges - TipRanks
Breakthrough: CKPT Secures FDA Approval and $416M Merger Deal in Transformative Year - Stock Titan
MUSTANG BIO, INC. SEC 10-K Report - TradingView
Journey Medical Reports 2024 Financial Results - TipRanks
FDA Green Light for Journey Medical's Rosacea Drug Reshapes 2024 Performance - StockTitan
Fortress Biotech Inc (FBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus
Fortress Biotech (NASDAQ:FBIOP) Trading Up 3.9% – Here’s Why - Defense World
Fortress Biotech (FBIO) Expected to Announce Earnings on Thursday - Defense World
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 - GlobeNewswire
Journey Medical Sets Date for 2024 Annual Results: Dermatology Leader's Financial Update - Stock Titan
Atria Investments Inc Buys 16,841 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
Partex And Fortress Biotech Announce Collaboration To Accelerate Biopharma Asset Evaluation - Nasdaq
Fortress Biotech, Partex Team Up for Asset Identification, Evaluation Using AI -March 17, 2025 at 09:36 am EDT - Marketscreener.com
Fortress Biotech partners with Partex for AI-driven drug discovery By Investing.com - Investing.com Australia
Fortress Biotech partners with Partex for AI-driven drug discovery - Investing.com
Partex NV and Fortress Biotech, Inc. Announce Strategic Collaboration to Leverage AI in Biopharmaceutical Drug Discovery - Nasdaq
Partex and Fortress Biotech Announce Strategic - GlobeNewswire
AI Breakthrough: Fortress Biotech's New Partnership Transforms Drug Development Process - StockTitan
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Equities Analysts Offer Predictions for FBIO Q1 Earnings - Defense World
Fortress Biotech (NASDAQ:FBIO) Receives “Buy” Rating from Roth Mkm - Defense World
Sun Pharma to Acquire Checkpoint Therapeutics in Oncology Expansion - Chemical Industry Digest
Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price - Simply Wall St
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma - Longview News-Journal
Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target - Marketscreener.com
Checkpoint (CKPT) Shares Skyrocket After A Takeover Agreement - Stocks Telegraph
Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma -March 10, 2025 at 06:24 am EDT - Marketscreener.com
Sun Pharma Pays 66% Premium in $355M Checkpoint Therapeutics Acquisition - Stock Titan
Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -March 10, 2025 at 04:50 am EDT - Marketscreener.com
Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics for $355 million; shares edge higher - Mint
Checkpoint Therapeutics rises on $355 million Sun Pharma buyout deal - TradingView
Sun Pharma to acquire US based onco-derma firm Checkpoint for $355 mn - Business Standard
Sun Pharma to acquire 100% stake in Nasdaq-listed Checkpoint Therapeutics - Business Standard
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million - Reuters
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million -March 09, 2025 at 11:49 pm EDT - Marketscreener.com
Sun Pharma to Acquire Checkpoint Therapeutics - Quantisnow
India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln By Investing.com - Investing.com Australia
India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln - Investing.com
Sun Pharma to acquire Checkpoint Therapeutics for Rs 3,000 crore - Business Upturn
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):